STAT August 2, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning and happy Friday. We discuss a new innovative immunotherapy, and we take a look at some of the earnings highlights yesterday.
FDA approves immunotherapy for soft-tissue cancer
The Food and Drug Administration has approved a T cell immunotherapy from Adaptimmune Therapeutics for a rare cancer that arises in the body’s soft tissues, extending the power of immunotherapies to difficult-to-reach sarcomas.
The medicine, called Tecelra, is what’s known as a T cell receptor therapy. The approach has similarities to the CAR-T treatments that have dramatically improved the care of some blood cancers, but it has tricks...
Today's Sponsors
Today's Sponsor